Depsipeptide
Depsipeptide is a pharmaceutical drug with 8 clinical trials. Historical success rate of 40.0%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
4
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
33.3%
2 of 6 finished
66.7%
4 ended early
0
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum
Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies
FR901228 in Treating Patients With Recurrent High-Grade Gliomas
FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer
Clinical Trials (8)
FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum
Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies
FR901228 in Treating Patients With Recurrent High-Grade Gliomas
FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer
S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium
A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma
A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide.
All 8 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 8